Erlizumab
Erlizumab
Erlizumab (pronounced: er-li-zoo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases.
Etymology
The name "Erlizumab" is derived from the International Nonproprietary Names (INN), where "zu" signifies humanized, "mab" stands for monoclonal antibody, and "Erl" is a prefix used by the pharmaceutical company that developed the drug.
Usage
Erlizumab is used in the treatment of several autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. It works by targeting and neutralizing specific proteins that are responsible for the inflammatory response in these conditions.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune Disease: An illness that occurs when the body tissues are attacked by its own immune system.
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Psoriasis: A skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp.
- Crohn's Disease: A type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.
External links
- Medical encyclopedia article on Erlizumab
- Wikipedia's article - Erlizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski